Bristol-Myers Squibb Co.

NYSE:BMY   3:59:59 PM EDT
63.86
+1.62 (+2.60%)
Share Repurchases, Other Pre-Announcement

Bristol Myers Squibb Says 2022 Revenue Expected To Be About $47 Billion

Published: 01/10/2022 11:57 GMT
Bristol-Myers Squibb Co. (BMY) - Bristol Myers Squibb - 2022 Revenue Expected to Be About $47 Billion, Representing an Increase in the Low-single Digits.
FY2022 Earnings per Share View $7.85, Revenue View $47.74 Billion -- Refinitiv Ibes Data (analyst estimates).
Bristol Myers Squibb - 2022 Non-GAAP EPS Expected to Be in Range of $7.65 - $7.95.
Bristol Myers Squibb - Reaffirming 2020-2025 Long-term Revenue, Operating Margin Targets Communicated in January 2021.
Bristol Myers - $5 Billion Accelerated Share Repurchase Agreement to Be Executed During Q1; Asr is Part of Prior Disclosed Authorization.
Bristol Myers Squibb - 2022 Sales From Key Loss of Exclusivity (loe) Brands, Which Represent Revlimid and Abraxane, Expected to Be About $10.5 Billion.
Bristol Myers Squibb - Opdivo, Yervoy and Eliquis Expected to Contribute About $8-$10 Billion in Revenue Growth During 2020-2025.
Bristol Myers Squibb - Continuing Business Expected to Grow in Low-double Digits and Contribute About $36.5 Billion in 2022.
Bristol Myers Squibb - 2022 Revlimid Sales Expected to Be $9.5 - $10 Billion.